<DOC>
	<DOCNO>NCT02012192</DOCNO>
	<brief_summary>Epithelial ovarian cancer ( EOC ) lethal gynaecological malignancy cause 41900 death annually Europe . The predominance aggressive Type II tumour , characterise high frequency p53 mutation , primary acquire resistance platinum-based chemotherapy profoundly contribute high mortality rate . With current standard therapy median overall survival metastatic platinum-resistant ( Pt-R ) ovarian cancer patient 14 month . There press need effective , innovative treatment strategy particularly improve survival subgroup EOC patient . This drug strategy target central driver tumour aggressiveness metastatic ability , namely mutant p53 , via innovative new Hsp90 ( heat shock protein 90 ) inhibition mechanism . The advanced , second-generation Hsp90 inhibitor use , Ganetespib . The first part ( Phase I ) GANNET53 trial test safety Ganetespib new combination standard chemotherapy ( Paclitaxel weekly ) Pt-R EOC patient . The second part ( randomised Phase II ) examine efficacy Ganetespib combination standard chemotherapy versus standard chemotherapy alone EOC patient Pt-R tumour .</brief_summary>
	<brief_title>GANNET53 : Ganetespib Metastatic , p53-mutant , Platinum-resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Ability understand willingness sign date write informed consent document Female patient ≥18 year age Highgrade serous , highgrade endometrioid , undifferentiated epithelial ovarian , fallopian tube primary peritoneal cancer Patients part II : Highgrade serous , highgrade endometrioid , undifferentiated epithelial ovarian , fallopian tube primary peritoneal cancer confirm central histopathology archival formalinfixed paraffin embed ( FFPE ) freshfrozen tumour sample . • Platinumresistant disease : primary platinumresistant disease : progression &gt; 1 month ≤ 6 month completion primary platinumbased therapy secondary platinumresistant disease ( include secondary platinumrefractory disease ) : progression ≤ 6 month ( ) reiterative platinumbased therapy Patients must disease measurable accord RECIST 1.1 assessable accord GCIG ( Eastern Cooperative Oncology Group ) CA125 criterion ECOG performance status 01 Life expectancy least 3 month assess investigator Adequate function bone marrow : Platelets ≥100 x 109/L Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Haemoglobin ≥ 8.5 g/dl . Patients may receive blood transfusion ( ) maintain haemoglobin value &gt; 8.5 g/dl . Adequate organ function : Creatinine &lt; 2 mg/dl ( &lt; 177 µmol/L ) Total bilirubin ≤ 1.5 x upper limit normal SGOT ( serum glutamate oxaloacetate transaminase ) /SGPT ( serum glutamate pyruvate transaminase ) ( AST/ALT ) ≤ 3 x upper limit normal Urinanalysis urine dipstick proteinuria less 2+ . Patients ≥ 2+ dipstick undergo 24hour urine collection must demonstrate &lt; 1 g protein/24 hour . Alternatively , proteinuria test perform accord local standard Negative urine/serum pregnancy test woman childbearing potential ( WOCBP , see section 5 ) . WOCBP sexually active , agree use highly effective mean contraception study least 6 month poststudy treatment . Allowed accept effective nonhormonal method contraception sexual abstinence vasectomise partner ( &gt; 3 month previously ) . Vasectomy confirm two negative semen analysis . Availability archival ovarian cancer tissue central histopathological review p53 mutational analysis Ovarian tumour low malignant potential ( i.e . borderline tumour ) Primary platinumrefractory disease ( progression primary platinumbased chemotherapy ) PRIOR , CURRENT OR PLANNED TREATMENT : Previous treatment &gt; 2 chemotherapy regimen platinumresistant setting ( exclude target endocrine therapy ) . More 4 previous line chemotherapy . Major surgery within 2 week prior first dose ganetespib PRIOR OR CONCOMITANT CONDITIONS OR PROCEDURES : Patients history prior malignancy , except , diseasefree timeframe ≥ 3 year prior randomisation . Patients prior insitu carcinoma , except : complete removal tumour give Known history severe ( grade 3 4 ) allergic hypersensitivity reaction excipients ( e.g. , polyethylene glycol [ PEG ] 300 Polysorbate 80 ) History intolerance hypersensitivity paclitaxel and/or adverse event relate paclitaxel result paclitaxel permanently discontinue Peripheral neuropathy grade &gt; 2 per NCI CTCAE ( Common Toxicity Criteria Adverse Effects ) , version 4.03 , within 4 week prior randomisation Clinical symptomatic bowel obstruction time screen Left ventricular ejection fraction define MUGA ( multigated acquisition ) /ECHO institutional low limit normal Patients symptomatic brain metastasis Significant cardiac disease : New York Heart Association ( NYHA ) Class 3 4 ; myocardial infarction within past 6 month ; unstable angina ; coronary angioplasty coronary artery bypass graft ( CABG ) within past 6 month ; uncontrolled atrial ventricular cardiac arrhythmia . History prolong QT syndrome , family member prolong QT syndrome QTc ( correct QT interval ) interval &gt; 470 msec 3 consecutive EKG value average Ventricular tachycardia supraventricular tachycardia require treatment Class Ia antiarrhythmic drug ( e.g. , quinidine , procainamide , disopyramide ) Class III antiarrhythmic drug ( e.g. , sotalol , amiodarone , dofetilide ) . Use antiarrhythmic drug permit Second thirddegree atrioventricular ( AV ) block , except : treated permanent pacemaker Complete leave bundle branch block ( LBBB ) Any condition , opinion investigator , may compromise safety , compliance patient , would preclude patient successful completion study . Participation another clinical study experimental therapy within 28 day start treatment . Women pregnant lactating</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>High-grade serous</keyword>
	<keyword>high-grade endometrioid</keyword>
	<keyword>undifferentiated</keyword>
</DOC>